We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+2.97%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$1.72B
AUM Growth
-$344M
Cap. Flow
-$310M
Cap. Flow %
-18%
Top 10 Hldgs %
22.96%
Holding
279
New
14
Increased
72
Reduced
169
Closed
14

Sector Composition

Rank Sector Weight
1 Technology 27.05%
2 Healthcare 26.07%
3 Industrials 15.04%
4 Consumer Discretionary 11.17%
5 Communication Services 6.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WIX icon
51
WIX.com
WIX
$2.52B
$9.18M 0.53%
117,380
-44,620
-28% -$3.08M
CCSI icon
52
Consensus Cloud Solutions
CCSI
$647M
$8.96M 0.52%
189,430
-28,065
-13% -$1.44M
ACAD icon
53
Acadia Pharmaceuticals
ACAD
$5.03B
$8.57M 0.5%
523,870
-19,658
-4% -$318K
TTGT icon
54
TechTarget
TTGT
$278M
$8.44M 0.49%
+142,597
New +$9.17M
LKQ icon
55
LKQ Corp
LKQ
$6.29B
$8.43M 0.49%
178,845
-182,095
-50% -$9.52M
ATEN icon
56
A10 Networks
ATEN
$1.95B
$8.13M 0.47%
612,434
-1,683
-0.3% -$23.9K
ACLS icon
57
Axcelis
ACLS
$4.33B
$7.89M 0.46%
130,320
-357
-0.3% -$23.1K
CSW
58
CSW Industrials
CSW
$5.71B
$7.88M 0.46%
65,748
-6,573
-9% -$804K
ITRN icon
59
Ituran Location and Control
ITRN
$1.05B
$7.79M 0.45%
333,915
-16,195
-5% -$403K
RXT icon
60
Rackspace Technology
RXT
$1.24B
$7.53M 0.44%
1,845,838
-820,466
-31% -$4.76M
FOLD
61
DELISTED
Amicus Therapeutics
FOLD
$7.46M 0.43%
714,409
-199,866
-22% -$2.23M
SNBR
62
DELISTED
Sleep Number
SNBR
$7.3M 0.42%
215,993
-50,797
-19% -$2.04M
MODN
63
DELISTED
MODEL N, INC.
MODN
$7.15M 0.41%
208,962
-758
-0.4% -$21.9K
WLDN icon
64
Willdan Group
WLDN
$1.3B
$6.71M 0.39%
453,117
-68,564
-13% -$1.64M
STRA icon
65
Strategic Education
STRA
$1.92B
$6.24M 0.36%
101,532
-82,334
-45% -$5.54M
DOCS icon
66
Doximity
DOCS
$4.88B
$6.19M 0.36%
+204,911
New +$7.51M
HAE icon
67
Haemonetics
HAE
$4B
$6.12M 0.35%
82,623
+5,297
+7% +$380K
GDDY icon
68
GoDaddy
GDDY
$11.5B
$6.04M 0.35%
85,269
-101,526
-54% -$7.64M
NXGN
69
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
$5.9M 0.34%
+333,242
New +$5.78M
HLIT icon
70
Harmonic Inc
HLIT
$1.28B
$5.84M 0.34%
447,007
+908
+0.2% +$9.81K
TRAK icon
71
ReposiTrak
TRAK
$159M
$5.8M 0.34%
1,083,527
-15,712
-1% -$85.5K
UFPT icon
72
UFP Technologies
UFPT
$2.43B
$5.68M 0.33%
66,217
+140
+0.2% +$12.3K
ON icon
73
ON Semiconductor
ON
$31.6B
$5.58M 0.32%
89,554
-204,290
-70% -$13.2M
INSM icon
74
Insmed
INSM
$28.6B
$5.36M 0.31%
248,930
-63,154
-20% -$1.51M
ROAD icon
75
Construction Partners
ROAD
$6.77B
$5.36M 0.31%
204,292
+1,195
+0.6% +$31.3K

Similar funds

Rice Hall James & Associates's Q3 2022 Portfolio in Review

As of Q3 2022, Rice Hall James & Associates held 279 positions worth $1.72B, down 17% from $2.07B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Rice Hall James & Associates withdrew a net $310M in Q3 2022, closing 14 positions and reducing 169 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $7.39M position sold in full.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Rice Hall James & Associates opened a new position in TechTarget worth $8.44M.

  • Rice Hall James & Associates's largest Q3 2022 buy was TechTarget: 142,597 shares worth $8.44M.
  • Rice Hall James & Associates added most to Upland Software in Q3 2022, an estimated $3.67M increase.
  • Rice Hall James & Associates's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $26.8M.
  • Rice Hall James & Associates fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $7.39M.
  • Rice Hall James & Associates's ten largest holdings make up 23% of its $1.72B portfolio in Q3 2022.
  • Rice Hall James & Associates opened 14 new positions and closed 14 in Q3 2022.
  • Rice Hall James & Associates's portfolio value fell 17% quarter-over-quarter to $1.72B.

Based on Rice Hall James & Associates's 13F filing for Q3 2022, filed 1 Nov 2022.